Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study

M-B Jensen; C B Pedersen; M-A Misiakou; M-L M Talman; L Gibson; U B Tange; H Kledal; I Vejborg; N Kroman; F C Nielsen; B Ejlertsen; M Rossing

doi:10.1038/s41523-023-00551-0

Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study

M-B Jensen^*, C B Pedersen, M-A Misiakou, M-L M Talman, L Gibson, U B Tange, H Kledal, I Vejborg, N Kroman, F C Nielsen, B Ejlertsen, M Rossing

^*Corresponding author for this work

2 Citations (Scopus)

Abstract

Estrogen receptor (ER) and human epidermal growth factor 2 (HER2) expression guide the use of neoadjuvant chemotherapy (NACT) in patients with early breast cancer. We evaluate the independent predictive value of adding a multigene profile (CIT256 and PAM50) to immunohistochemical (IHC) profile regarding pathological complete response (pCR) and conversion of positive to negative axillary lymph node status. The cohort includes 458 patients who had genomic profiling performed as standard of care. Using logistic regression, higher pCR and node conversion rates among patients with Non-luminal subtypes are shown, and importantly the predictive value is independent of IHC profile. In patients with ER-positive and HER2-negative breast cancer an odds ratio of 9.78 (95% CI 2.60;36.8), P < 0.001 is found for pCR among CIT256 Non-luminal vs. Luminal subtypes. The results suggest a role for integrated use of up-front multigene subtyping for selection of a neoadjuvant approach in ER-positive HER2-negative breast cancer.

Original language	English
Article number	47
Journal	Current Medical Literature. Breast Cancer
Volume	9
Issue number	1
Pages (from-to)	47
ISSN	2374-4677
DOIs	https://doi.org/10.1038/s41523-023-00551-0
Publication status	Published - Dec 2023

Access to Document

10.1038/s41523-023-00551-0Licence: CC BY

Cite this

Jensen, M.-B., Pedersen, C. B., Misiakou, M.-A., Talman, M.-L. M., Gibson, L., Tange, U. B., Kledal, H., Vejborg, I., Kroman, N., Nielsen, F. C., Ejlertsen, B., & Rossing, M. (2023). Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study. Current Medical Literature. Breast Cancer, 9(1), 47. Article 47. https://doi.org/10.1038/s41523-023-00551-0

Jensen, M-B, Pedersen, CB, Misiakou, M-A , Talman, M-LM , Gibson, L , Tange, UB, Kledal, H, Vejborg, I , Kroman, N , Nielsen, FC , Ejlertsen, B & Rossing, M 2023, 'Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study', Current Medical Literature. Breast Cancer, vol. 9, no. 1, 47, pp. 47. https://doi.org/10.1038/s41523-023-00551-0

@article{5e182e9d999d42c7ad99b176bcf230e1,

title = "Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study",

abstract = "Estrogen receptor (ER) and human epidermal growth factor 2 (HER2) expression guide the use of neoadjuvant chemotherapy (NACT) in patients with early breast cancer. We evaluate the independent predictive value of adding a multigene profile (CIT256 and PAM50) to immunohistochemical (IHC) profile regarding pathological complete response (pCR) and conversion of positive to negative axillary lymph node status. The cohort includes 458 patients who had genomic profiling performed as standard of care. Using logistic regression, higher pCR and node conversion rates among patients with Non-luminal subtypes are shown, and importantly the predictive value is independent of IHC profile. In patients with ER-positive and HER2-negative breast cancer an odds ratio of 9.78 (95% CI 2.60;36.8), P < 0.001 is found for pCR among CIT256 Non-luminal vs. Luminal subtypes. The results suggest a role for integrated use of up-front multigene subtyping for selection of a neoadjuvant approach in ER-positive HER2-negative breast cancer.",

author = "M-B Jensen and Pedersen, {C B} and M-A Misiakou and Talman, {M-L M} and L Gibson and Tange, {U B} and H Kledal and I Vejborg and N Kroman and Nielsen, {F C} and B Ejlertsen and M Rossing",

note = "{\textcopyright} 2023. The Author(s).",

year = "2023",

month = dec,

doi = "10.1038/s41523-023-00551-0",

language = "English",

volume = "9",

pages = "47",

journal = "Current Medical Literature. Breast Cancer",

issn = "2374-4677",

publisher = "Remedica Medical Education and Publishing Ltd",

number = "1",

}

TY - JOUR

T1 - Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer

T2 - a Copenhagen Breast Cancer Genomics Study

AU - Jensen, M-B

AU - Pedersen, C B

AU - Misiakou, M-A

AU - Talman, M-L M

AU - Gibson, L

AU - Tange, U B

AU - Kledal, H

AU - Vejborg, I

AU - Kroman, N

AU - Nielsen, F C

AU - Ejlertsen, B

AU - Rossing, M

PY - 2023/12

Y1 - 2023/12

N2 - Estrogen receptor (ER) and human epidermal growth factor 2 (HER2) expression guide the use of neoadjuvant chemotherapy (NACT) in patients with early breast cancer. We evaluate the independent predictive value of adding a multigene profile (CIT256 and PAM50) to immunohistochemical (IHC) profile regarding pathological complete response (pCR) and conversion of positive to negative axillary lymph node status. The cohort includes 458 patients who had genomic profiling performed as standard of care. Using logistic regression, higher pCR and node conversion rates among patients with Non-luminal subtypes are shown, and importantly the predictive value is independent of IHC profile. In patients with ER-positive and HER2-negative breast cancer an odds ratio of 9.78 (95% CI 2.60;36.8), P < 0.001 is found for pCR among CIT256 Non-luminal vs. Luminal subtypes. The results suggest a role for integrated use of up-front multigene subtyping for selection of a neoadjuvant approach in ER-positive HER2-negative breast cancer.

AB - Estrogen receptor (ER) and human epidermal growth factor 2 (HER2) expression guide the use of neoadjuvant chemotherapy (NACT) in patients with early breast cancer. We evaluate the independent predictive value of adding a multigene profile (CIT256 and PAM50) to immunohistochemical (IHC) profile regarding pathological complete response (pCR) and conversion of positive to negative axillary lymph node status. The cohort includes 458 patients who had genomic profiling performed as standard of care. Using logistic regression, higher pCR and node conversion rates among patients with Non-luminal subtypes are shown, and importantly the predictive value is independent of IHC profile. In patients with ER-positive and HER2-negative breast cancer an odds ratio of 9.78 (95% CI 2.60;36.8), P < 0.001 is found for pCR among CIT256 Non-luminal vs. Luminal subtypes. The results suggest a role for integrated use of up-front multigene subtyping for selection of a neoadjuvant approach in ER-positive HER2-negative breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85160930575&partnerID=8YFLogxK

U2 - 10.1038/s41523-023-00551-0

DO - 10.1038/s41523-023-00551-0

M3 - Journal article

C2 - 37258527

SN - 2374-4677

VL - 9

SP - 47

JO - Current Medical Literature. Breast Cancer

JF - Current Medical Literature. Breast Cancer

IS - 1

M1 - 47

ER -

Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this